Mounjaro (tirzepatide) is a prescription-only medication in the United States and cannot be purchased over the counter, online without a prescription, or from a pharmacy without a prescriber’s order. Getting one typically involves a visit with a physician, nurse practitioner, or other licensed prescriber who determines whether you meet the clinical criteria for the drug. The process sounds straightforward, but in practice, insurance hurdles, supply fluctuations, and the distinction between on-label and off-label prescribing make the path from “I want to try Mounjaro” to actually injecting the first dose more complicated than most people expect.
What Mounjaro Is Approved For
Mounjaro’s active ingredient, tirzepatide, is a dual-action drug that activates two gut-hormone receptors at once, one for GIP and one for GLP-1. That dual mechanism is what sets it apart from single-receptor drugs and allows once-weekly dosing thanks to its chemical structure that keeps it active in the body for days.1PubMed Central. Insights into the Mechanism of Action of Tirzepatide: A Narrative Review The FDA initially approved Mounjaro specifically for improving blood-sugar control in adults with type 2 diabetes. Clinical trials showed substantial reductions in hemoglobin A1c (roughly 1.2 to 2.1 percentage points compared with placebo) alongside significant weight loss of up to about 15.5 kg.2PubMed Central. Tirzepatide for type 2 diabetes
Eli Lilly later received a separate FDA approval for tirzepatide under the brand name Zepbound, which is specifically indicated for chronic weight management in adults with obesity or overweight with at least one weight-related health condition. This distinction matters: Mounjaro and Zepbound contain the same molecule at the same doses, but they carry different brand names, different labeling, and often different insurance coverage rules. If your doctor wants to prescribe tirzepatide for weight loss rather than diabetes, the prescription may be written as Zepbound rather than Mounjaro, and the insurance pathway can differ substantially.
Who Qualifies for a Prescription
For the diabetes indication, you generally need a diagnosis of type 2 diabetes and a clinical picture where your current treatment isn’t achieving adequate blood-sugar control. Your prescriber will review your A1c levels, current medications, kidney function, and other factors before writing the script. Tirzepatide is not approved for type 1 diabetes.
For weight management under the Zepbound label, the standard eligibility criteria mirror those of other FDA-approved anti-obesity medications: a body mass index of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnea. Your doctor makes the determination, and many will also want to confirm that you’ve attempted lifestyle changes like diet and exercise before adding a prescription medication.
There are people who should not take tirzepatide at all. The FDA’s boxed warning for GLP-1 receptor agonists states that these drugs should not be used in anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2.3Cancer Network. Evaluating Thyroid Cancer Risk After GLP-1 Receptor Agonist Administration – Section: Clinical Recommendations for Oncologists A history of severe pancreatitis, severe gastrointestinal disease, or pregnancy also typically rules out these medications. Your prescriber should screen for these before writing a prescription.
The Practical Steps to Getting a Prescription
The most common route is a visit with your primary care doctor or an endocrinologist. You can also see an obesity medicine specialist, an internist, or in many states, a nurse practitioner or physician assistant with prescribing authority. The appointment itself usually involves a basic health assessment: your weight, height, BMI, blood pressure, relevant lab work (blood sugar, A1c, lipid panel, thyroid function), and a conversation about your medical history and goals.
Telehealth has expanded access considerably. Several online health platforms now connect patients with licensed prescribers who can evaluate you via video visit and send a prescription to your pharmacy if you qualify. The quality of these services varies. Reputable ones require a real medical evaluation, review your labs, and follow up regularly. Less scrupulous operations may rush through evaluations or prescribe without adequate screening. If a telehealth service doesn’t ask about your medical history, current medications, or contraindications, that’s a red flag.
Once you have the prescription in hand, your pharmacy fills it like any other injectable medication. Mounjaro comes as a prefilled pen with a hidden needle, designed for self-injection once a week. Your prescriber will typically start you at the lowest dose (2.5 mg weekly) and increase gradually over several months. This titration schedule is designed to let your body adjust and reduce gastrointestinal side effects like nausea, which are common in the early weeks.
Insurance Coverage and Prior Authorization
This is where most people hit a wall. Having a valid prescription doesn’t guarantee you can afford the medication. Without insurance, Mounjaro’s list price runs over $1,000 per month. Even with insurance, coverage is far from automatic.
Most state Medicaid programs and Medicare do not cover anti-obesity medications, and private insurance plans frequently restrict access by requiring prior authorization.4JAMA Health Forum. Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults Prior authorization means your doctor has to submit paperwork to your insurer proving you meet specific clinical criteria before the plan will pay. That process can take days to weeks, and denial rates are not trivial. Among Medicare Part D plans that did cover tirzepatide, prior authorization requirements surged from below 25% to about 83% by the third quarter of 2024.5JAMA Network Open. Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans That sharp increase means even people with coverage are increasingly likely to face delays and paperwork before getting their first fill.
If your insurance denies coverage, you have a few options. Your doctor can file an appeal, sometimes with additional clinical documentation. Eli Lilly offers a savings card program for commercially insured patients that can substantially reduce out-of-pocket costs, though the specifics change frequently. Some patients also turn to compounding pharmacies or patient assistance programs, each with its own set of trade-offs discussed below.
Off-Label Prescribing for Weight Loss
Before Zepbound received its own approval, many doctors were already prescribing Mounjaro off-label for weight loss in patients without type 2 diabetes. Off-label prescribing is legal and common across medicine. A doctor can prescribe any FDA-approved drug for a use they consider medically appropriate, even if that specific use isn’t on the label. The clinical rationale was obvious: the diabetes trials showed dramatic weight loss as a “side effect,” and the drug’s mechanism of action supported its potential in obesity treatment.
Analyses of off-label tirzepatide use have found that the drug does produce significant weight reduction and improved metabolic outcomes in people without a formal diabetes diagnosis. However, using it outside the approved indication introduces risks related to less robust evidence, potential for adverse events, and gaps in monitoring.6Health Studies: Global Knowledge. OFF-LABEL USE OF TIRZEPATIDE (MOUNJARO®) FOR WEIGHT LOSS: HEALTH BENEFITS AND RISKS Incretin-based therapies like tirzepatide have fundamentally reshaped treatment for both type 2 diabetes and obesity, but the evidence base remains strongest for their approved indications.7PubMed Central. A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Efficacy and Adverse Events
From a practical standpoint, an off-label prescription for Mounjaro (written specifically as Mounjaro, not Zepbound) may actually be easier to get covered by some insurance plans if you have a type 2 diabetes diagnosis, because diabetes coverage is more established. If you don’t have diabetes and want tirzepatide purely for weight management, your prescriber will likely write for Zepbound, and you’ll face the coverage landscape described above, which is generally less favorable for anti-obesity medications.
Compounded Versions and Why They Carry Extra Risk
During periods of drug shortage, compounding pharmacies have been permitted to produce tirzepatide copies. These are not generic versions. Generics go through rigorous FDA review to prove they’re equivalent to the brand-name drug. Compounded medications do not. They’re mixed by pharmacies under state-level regulation, and the FDA does not approve them for safety or effectiveness.
Some small studies have shown positive clinical outcomes in patients receiving compounded semaglutide and tirzepatide. But significant legal and safety concerns remain, because compounded incretins bypass the FDA approval process entirely.8PubMed Central. Compounded incretins in clinical practice: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy The risks include inconsistent dosing (the amount of active ingredient can vary from vial to vial), contamination, and the absence of the long-term safety data that FDA-approved products must demonstrate. The FDA has issued warnings about adverse events linked to compounded GLP-1 medications, including hospitalizations.
If you’re considering a compounded version because of cost or availability, understand the trade-off clearly. You may save money, but you’re giving up the quality controls that come with an FDA-approved product. Talk to your prescriber about this option explicitly rather than sourcing it independently online, where fraudulent products are common.
What Happens When You Stop Taking It
One of the most important things to understand before starting Mounjaro is that the weight loss it produces depends on continued treatment. This isn’t a course of antibiotics that you finish and move on from. Tirzepatide works by altering your appetite signals and metabolic processes while you’re taking it. When you stop, those signals revert.
The evidence here is unambiguous. In one trial, participants who took tirzepatide for 36 weeks lost an average of about 21% of their body weight. Those who then switched to placebo regained an average of 14% of their weight over the following year, while those who continued tirzepatide lost an additional 5.5%.9PubMed Central. Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies A follow-up analysis of the same trial found that most participants who stopped tirzepatide regained a quarter or more of the weight they had lost within a year, and the metabolic improvements they had experienced, like better blood pressure and cholesterol, reversed along with the weight.10PubMed Central. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial
This means you should think of Mounjaro as a long-term or potentially indefinite medication, similar to blood pressure drugs or statins. Stopping is an option, but it comes with predictable consequences. Some clinicians are exploring maintenance strategies, like stepping down to a lower dose rather than stopping entirely, but robust data on those approaches is still developing. The weight-regain pattern is one of the strongest reasons to make sure your insurance and financial plan can sustain the cost before you start.
Side Effects You Should Know About
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, decreased appetite, and constipation. These tend to be worst during the first few weeks and when your dose increases. Most people find them manageable, and they often improve over time. Eating smaller meals, avoiding fatty or greasy food, and staying hydrated can help. If nausea is severe, your prescriber may slow down the dose escalation schedule.
Less common but more serious risks include pancreatitis, gallbladder problems (particularly gallstones, which become more likely during rapid weight loss), and the thyroid concerns mentioned in the contraindications section. Any persistent, severe abdominal pain should be evaluated promptly.
One side effect that gets less public attention but matters enormously if you’re planning surgery: tirzepatide and other GLP-1 receptor agonists slow stomach emptying. This means that even if you follow the standard instruction to fast before a procedure, your stomach may still contain food or liquid. The UK’s medicines regulator has warned that patients on these drugs face an increased risk of pulmonary aspiration during general anesthesia or deep sedation.11BMJ. GLP-1 agonists may raise risk of pulmonary aspiration during surgery, MHRA warns Gastric imaging studies have shown that roughly 56% of patients on GLP-1 receptor agonists still had a non-empty stomach after following standard fasting protocols, compared with about 18% of people not on these drugs. Research suggests that stopping the medication less than two weeks before a procedure may not be enough to normalize stomach emptying, and symptomatic patients may need to stop three weeks or more in advance.12Korean Journal of Anesthesiol. Blamed but not at fault: anti-obesity medication adverse effects misidentified as perioperative complications — a comprehensive review and medicolegal warning for anesthesiologists If you’re on Mounjaro and have any upcoming surgery, dental procedure under sedation, or endoscopy, tell your surgeon and anesthesiologist well in advance.
Navigating the Shortage and Supply Issues
Tirzepatide has been intermittently affected by supply shortages since its launch, driven by extraordinary demand that outstripped manufacturing capacity. During shortage periods, certain dose strengths may be unavailable at pharmacies for weeks at a time. This creates a practical problem for patients mid-treatment, because skipping doses or abruptly switching strengths can disrupt the gradual titration schedule and worsen side effects.
If your pharmacy can’t fill your prescription, there are a few things to try before panicking. Ask whether a different dose strength is available, as your prescriber may be able to adjust your regimen temporarily. Check other pharmacies in your area, including specialty pharmacies that focus on injectable medications. Eli Lilly’s website maintains an updated list of which dose strengths are currently in shortage, which can save you time. Avoid the temptation to stockpile doses or buy from unverified online sellers, both of which create their own risks.
Telehealth Prescribing and What to Watch For
The explosion of telehealth platforms marketing GLP-1 prescriptions has created a two-tier landscape. On one side are legitimate medical practices that happen to operate via video visits: they take a thorough history, order labs, titrate doses carefully, and follow up regularly. On the other side are services optimized for speed and volume, where the “consultation” lasts five minutes and the prescription arrives before you’ve finished describing your medical history.
A few markers distinguish a good telehealth prescriber from a questionable one. A reputable service will require recent lab work or order new labs before prescribing. It will ask detailed questions about your thyroid history, pancreatic health, and current medications. It will start you at the lowest dose and schedule follow-up appointments to check your progress and adjust the dose. It will have a real clinician available if you experience side effects. And it will not guarantee you a prescription before the evaluation, because the whole point of a medical evaluation is that the answer might be no.
If a telehealth platform’s marketing promises Mounjaro “in minutes” or advertises a specific medication before you’ve even been evaluated, be cautious. A prescription for a powerful injectable medication should come after a thorough assessment, not as a product in an online shopping cart.
How Mounjaro Compares Practically to Other GLP-1 Options
If you’ve been researching weight-loss or diabetes medications, you’ve probably seen Ozempic (semaglutide) mentioned alongside Mounjaro. Both are weekly injectables that work through incretin hormone pathways, but tirzepatide’s dual-receptor action distinguishes it mechanistically. In head-to-head diabetes trials, tirzepatide showed better blood-sugar reduction and greater weight loss compared with the GLP-1 receptor agonist it was tested against.2PubMed Central. Tirzepatide for type 2 diabetes That doesn’t automatically make it the right choice for every patient. Side-effect profiles, insurance formulary placement, and individual response all vary. Some people do better on one than the other, and your prescriber may have practical reasons for recommending a specific option.
Oral semaglutide (Rybelsus) is another alternative for people who don’t want to inject. It’s taken daily as a pill rather than weekly by injection, and some insurance plans cover it more readily. However, its bioavailability is lower, and the dosing protocol is more demanding: you have to take it on an empty stomach with a small sip of water and wait at least 30 minutes before eating or taking other medications. For patients who prefer the simplicity of a weekly injection they don’t have to think about the rest of the week, tirzepatide or injectable semaglutide often wins on convenience.
The prescription process for all of these medications is essentially the same: you need a licensed prescriber, a qualifying diagnosis, and the patience to navigate insurance requirements. The medication your doctor ultimately recommends will depend on your specific clinical profile, what your insurance covers, and what’s currently available at your pharmacy.